The Patent Finder

Signe Biopharma Inc.

Also on record
Records under this name other than patents Signe Biopharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Signe Biopharma Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,563,249Receptor gene screening for detecting or diagnosing cancer
Lapsed on the fee record
Ended Oct 22, 2017 · USPTO record
Lapsed on the fee recordEnded Oct 22, 2017USPTO record
US 8,119,138Anti-Estrogen and Immune Modulator Combinations for Treating Breast Cancer
Lapsed on the fee record
Ended Feb 21, 2016 · High confidence
Lapsed on the fee recordEnded Feb 21, 2016High confidence
US 8,038,999Breast cancer eradication program
Lapsed on the fee record
Ended Oct 18, 2015 · USPTO record
Lapsed on the fee recordEnded Oct 18, 2015USPTO record
US 7,947,275Compositions and Methods for Demonstrating Secretory Immune System Regulation of Steroid Hormone Responsive Cancer Cell Growth
Lapsed on the fee record
Ended May 24, 2015 · Medium confidence
Lapsed on the fee recordEnded May 24, 2015Medium confidence
US 7,947,463Compositions and Methods for the Diagnosis, Treatment and Prevention of Steroid Hormone Responsive Cancers
Lapsed on the fee record
Ended May 24, 2015 · Medium confidence
Lapsed on the fee recordEnded May 24, 2015Medium confidence
US 7,863,011Screening Method for Predicting Susceptibility to Breast Cancer
Lapsed on the fee record
Ended Jan 4, 2015 · High confidence
Lapsed on the fee recordEnded Jan 4, 2015High confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited